Chen W, You J, Chen J, Zheng Q, Jiang JJ, Zhu YY. Modified model for end-stage liver disease improves short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2017; 23(40): 7303-7309 [PMID: 29142477 DOI: 10.3748/wjg.v23.i40.7303]
Corresponding Author of This Article
Yue-Yong Zhu, MD, Professor, Center for Liver Diseases, the First Affiliated Hospital, Fujian Medicine University, Fuzhou 350005, Fujian Province, China. zhuyueyong@fjmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Wei Chen, Jia You, Jing Chen, Qi Zheng, Jia-Ji Jiang, Yue-Yong Zhu, Center for Liver Diseases, the First Affiliated Hospital, Fujian Medicine University, Fuzhou 350005, Fujian Province, China
Author contributions: Chen W performed the majority of the research around this topic and wrote the manuscript; You J and Chen J were involved in the field study, analyzed the data and gave interpretations; Zheng Q and Jiang JJ performed the field study and provided valuable discussion and support; and Zhu YY was responsible for overall study concept and design, and revised the manuscript.
Institutional review board statement: This study was approved by the Institutional Review Board of the First Affiliated Hospital of Fujian Medicine University.
Informed consent statement: Written consent was obtained from all study participants, or the local guardian, in their first medical examination.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yue-Yong Zhu, MD, Professor, Center for Liver Diseases, the First Affiliated Hospital, Fujian Medicine University, Fuzhou 350005, Fujian Province, China. zhuyueyong@fjmu.edu.cn
Telephone: +86-591-87982053 Fax: +86-591-87982053
Received: June 27, 2017 Peer-review started: July 11, 2017 First decision: July 27, 2017 Revised: August 15, 2017 Accepted: September 5, 2017 Article in press: September 5, 2017 Published online: October 28, 2017 Processing time: 123 Days and 22 Hours
Core Tip
Core tip: This is a retrospective study to evaluate the short-term prognosis of hepatitis B virus (HBV)-acute-on-chronic liver failure (ACLF). Two hundred and thirty-six patients with HBV-ACLF were divided into two groups: survival group (S) and non-survival group (NS). In predicting 3-mo mortality using the model for MELD-LAC model, patients from the S group had significantly lower baseline scores compared with those from NS group using model for end-stage liver disease (MELD)-LAC model. AUROC was 0.859 calculated by using the MELD-LAC model, which was significantly higher than those calculated by using the lactate level (0.790) or MELD alone (0.818). The short-term prognosis of HBV-ACLF was improved by using a modified MELD including serum lactate from the present 6-year clinical study.
